Fig. 1From: Anti-drug antibodies and rheumatoid factor level in patients with rheumatoid arthritis using the infliximab biosimilar CT-P13Changes in ADA status at baseline and 52 weeks after switching from IFX to CT-P13 (A). Titers of ADA positive patients at baseline and 52 weeks after switching from IFX to CT-P13 (B)Back to article page